

LIVERACE™ SINGLEPLEX · PRODUCT OVERVIEW

Unlocking the Power of PCR-Free miRNA Biomarkers.

miRNA-122 detection from as little as 25 µL. Earlier, more liver-specific, and cross-species compatible. The precision your drug safety programme demands.



LiverAce™ SinglePlex

ACCURATE PCR-FREE
MIRNA-122 DETECTION

Luminex Ready

Cross-Species

25 µL Sample

- **Earlier than ALT/AST. Liver-specific.** miR-122 peaks hours before standard liver enzymes with no false positives from muscle injury or other pathologies, enabling fail-fast decisions in preclinical and clinical safety studies.
- **isomiR-level specificity.** Destina Chemistry overcomes the isomiR degradation problem that defeats PCR, delivering single-nucleotide resolution without amplification.
- **FDA Letter of Support.** miR-122 qualified via the IMI TransBioLine Consortium. The only commercial PCR-free single-well assay aligned with these regulatory scientific findings.

FOR RESEARCH USE ONLY · NOT FOR DIAGNOSTIC PROCEDURES

www.destinagenomics.com · info@destinagenomics.com

Av. de la Innovación 1, Office 112 · 18016 Granada, Spain

© 2026 Destina Genomica S.L.



LEARN MORE

PRODUCT

For Pharma & CROs

LiverAce™ SinglePlex

Accurate PCR-free miRNA-122 detection

miRNA-122 is a well-established early biomarker for liver toxicity, validated from organoids across small and large animal species to humans, rising much earlier and more liver-specific than AST/ALT. By overcoming the isomiR degradation challenge that defeats PCR, LiverAce™ SinglePlex delivers the **"Fail-Fast"** precision required for confident drug development decisions.



miRNA detection using immunoassay workflows and platforms

THE CHALLENGE · LIVER TOXICITY IN DRUG DEVELOPMENT

\$3B

AVG. COST PER APPROVED DRUG

#1

CAUSE OF DRUG WITHDRAWAL


750+

DRUGS LINKED TO LIVER TOXICITY

10M+

PATIENTS AFFECTED/YEAR

KEY FEATURES




Early Detection

miR-122 peaks hours ahead of ALT/AST



isomiR Specificity

PCR-Free single-nucleotide resolution




Liver-Specific

No false positives from muscle injury or other pathologies



25 µL Sample

For small animal models (mouse/rat) where blood volume is scarce



Luminex Ready


No capital investment needed



Cross-Species

Preclinical → Clinical

BIOMARKER DETECTION



REGULATORY VALIDATION

- ✓ FDA Letter of Support for miR-122 — IMI TransBioLine Consortium research
- ✓ Biomarker endorsed by EMA & FDA — qualified via IMI TransBioLine
- ✓ Only commercial single-well PCR-free miR-122 assay matching consortium scientific findings

COMPLETE DRUG DEVELOPMENT PROCESS — ONE ASSAY

PRE-CLINICAL

CLINICAL


In Vitro
Organoids


In Vivo
Animal Species


Clinical
Phase I → III

Same assay · Same sample type · Cross-species biomarker conservation



SCAN TO LEARN MORE

FOR RESEARCH USE ONLY

Not for diagnostic procedures

© 2026 Destina Genómica S.L.